Zogenix hands GW a win
A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Zogenix gets an unwelcome distraction from Fintepla
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
GW sets its sights on Zogenix and a new Epidiolex use
A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.
Zogenix’s pain is GW Pharma’s gain
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
Novel drug approvals set to hit a new record in 2018
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Neuren pays the price for sellside froth
The Australian group has found a partner for its lead asset at last, so why is the stock down?
